H. Res. 775 (119th)Bill Overview

Supporting the designation of September 2025 as "National Ovarian Cancer Awareness Month".

Simple ResolutionHealth|Health
Cosponsors
Support
Democratic
Introduced
Sep 30, 2025
Discussions
Bill Text
Current stageCommittee

Referred to the House Committee on Oversight and Government Reform.

Introduced
Committee
Floor
President
Law
Congressional Activities
01 · The brief
Simple ResolutionWhat this resolution actually does

This resolution asks the House of Representatives to support designating September 2025 as National Ovarian Cancer Awareness Month and to support the goals of that month. It is a non-binding statement made by one chamber and does not create new law, change federal programs, or require the President or federal agencies to act. In practice it primarily raises awareness, encourages outreach and education, and signals congressional attention to ovarian cancer issues. It does not itself provide funding or mandate policy changes.

This resolution expresses the House of Representatives' support for designating September 2025 as "National Ovarian Cancer Awareness Month." It lists facts about ovarian cancer (incidence, mortality, survival rates, lack of a reliable early detection test, symptoms, hereditary risk including BRCA, and care disparities affecting Black women, women of color, low-income and rural women, and some active-duty populations).

The text highlights gaps in guideline adherence (genetic counseling/testing), underfunding of ovarian cancer research relative to mortality, and the role of awareness campaigns and organizations that hold events in September.

The resolution itself is a non-binding statement endorsing the designation and the goals of increased awareness and education about ovarian cancer and its impacts.

Passage5/100

On content alone the resolution is very likely to be adopted by the House if brought to the floor because it is symbolic and noncontroversial. However, as a House simple resolution it does not itself create statutory law or require Senate or Presidential action; thus its chance of 'becoming law' is effectively negligible. If the intent were a nationwide formal designation requiring both chambers or an enacted statute, that would be a different vehicle and face modest procedural barriers but still likely achievable given the subject’s low controversy.

CredibilityAligned

Relative to its intended legislative type, this bill functions as a conventional commemorative House resolution: it clearly states the problem and purpose and formally designates September 2025 as National Ovarian Cancer Awareness Month, but it contains minimal operational, fiscal, or enforcement detail, which is consistent with its symbolic nature.

Contention15/100

Degree of desired action: liberals want follow-up funding and equity-focused programs; centrists want measured, accountable steps; conservatives prefer private/state solutions and limit federal spending.

02 · What it does

Who stands to gain, and who may push back.

Likely benefits vs burdens50% / 50%
Likely helpedCities

These are examples from the analysis, not a ranked list of the most-affected groups.

Likely helped
  • Potential benefitRaises public and provider awareness of ovarian cancer symptoms and risk factors, which supporters may argue could cont…
  • Potential benefitMay spur advocacy groups, health systems, and philanthropic organizations to increase outreach, screening-related educa…
  • Potential benefitHighlights disparities in incidence, diagnosis stage, treatment quality, and outcomes for Black women, women of color,…
Likely burdened
  • Potential burdenIs largely symbolic and does not authorize or appropriate funds, so critics may argue it will have limited concrete imp…
  • CitiesWithout accompanying funding or programmatic requirements, naming a month risks highlighting disparities and needs with…
  • Potential burdenMay produce only short-term attention during September with unclear long-term effects on policy or clinical practice, m…
03 · Why people split

Why the argument around this bill splits.

Degree of desired action: liberals want follow-up funding and equity-focused programs; centrists want measured, accountable steps; conservatives prefer private/state solutions and limit federal spending.
Progressive90%

A mainstream progressive would view this resolution positively as a needed recognition of a deadly disease that disproportionately harms marginalized groups.

They would welcome the attention to racial and geographic disparities, the emphasis on gaps in care and genetic testing, and the call to increase federal investment in research and education.

However, they might note the resolution is symbolic and press for concrete follow-on steps (funding, data collection, expanded access to genetic counseling and equitable treatment).

Leans supportive
Centrist85%

A pragmatic moderate would see the resolution as a sensible, largely noncontroversial awareness measure that highlights real problems (late-stage detection, disparities, and underfunding).

They would favor the symbolic designation but want clarity that it does not impose unfunded mandates or create new regulatory burdens.

They may encourage measured, evidence-based follow-up actions such as targeted research funding, improved data, and public health education campaigns with cost estimates.

Leans supportive
Conservative75%

A mainstream conservative would likely view the resolution as a benign, sympathetic awareness statement that many will support across the aisle.

They would appreciate awareness and support for patients but be wary of language in the text that could be used to justify expanded federal spending or mandates (for example, calls to increase federal investment and data collection).

They would prefer private-sector and nonprofit-led awareness and research efforts, state-level solutions, or voluntary federal support rather than new federal programs.

Leans supportive
04 · Can it pass?

The path through Congress.

Introduced

Reached or meaningfully advanced

Committee

Reached or meaningfully advanced

Floor

Still ahead

President

Still ahead

Law

Still ahead

Passage likelihood5/100

On content alone the resolution is very likely to be adopted by the House if brought to the floor because it is symbolic and noncontroversial. However, as a House simple resolution it does not itself create statutory law or require Senate or Presidential action; thus its chance of 'becoming law' is effectively negligible. If the intent were a nationwide formal designation requiring both chambers or an enacted statute, that would be a different vehicle and face modest procedural barriers but still likely achievable given the subject’s low controversy.

Scope and complexity
24%
Scopenarrow
24%
Complexitylow
Why this could stall
  • Whether House leadership will prioritize floor consideration and move the resolution out of committee to the floor (procedural scheduling is the main near‑term uncertainty).
  • Whether a companion or comparable measure will be introduced in the Senate; without a Senate measure the designation will remain a House expression.
05 · Recent votes

Recent votes on the bill.

No vote history yet

The bill has not accumulated any surfaced votes yet.

06 · Go deeper

Go deeper than the headline read.

Included on this page

Degree of desired action: liberals want follow-up funding and equity-focused programs; centrists want measured, accountable steps; conserva…

On content alone the resolution is very likely to be adopted by the House if brought to the floor because it is symbolic and noncontroversi…

Unlocked analysis

Relative to its intended legislative type, this bill functions as a conventional commemorative House resolution: it clearly states the problem and purpose and formally designates September 2025 as National Ovarian Cance…

Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.

Perspective breakdownsPassage barriersLegislative design reviewStakeholder impact map
Open full analysis